Whitney Ijem
Stock Analyst at Canaccord Genuity
(3.19)
# 1,059
Out of 4,667 analysts
82
Total ratings
39.06%
Success rate
4.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $80 | $59.36 | +34.77% | 5 | Nov 19, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $39 | $12.96 | +200.97% | 5 | Nov 19, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $90 | $13.12 | +585.98% | 5 | Nov 19, 2024 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $6 → $8 | $2.01 | +298.01% | 8 | Nov 15, 2024 | |
| PASG Passage Bio | Maintains: Buy | $13 | $0.51 | +2,430.66% | 4 | Nov 14, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $121 | $46.40 | +160.78% | 7 | Nov 12, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $148 → $150 | $109.40 | +37.11% | 3 | Nov 7, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $29 → $32 | $4.55 | +603.30% | 4 | Nov 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sell | $361 → $408 | $447.41 | -8.81% | 7 | Nov 6, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $366 → $384 | $248.79 | +54.35% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $62.56 | +34.27% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 | $2.22 | +620.72% | 5 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $28 | $1.40 | +1,900.00% | 4 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $86 | $16.17 | +431.85% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.35 | +566.67% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $88.63 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $16 | $0.78 | +1,964.52% | 4 | Jul 23, 2019 |
Rhythm Pharmaceuticals
Nov 19, 2024
Maintains: Buy
Price Target: $80
Current: $59.36
Upside: +34.77%
Rocket Pharmaceuticals
Nov 19, 2024
Maintains: Buy
Price Target: $39
Current: $12.96
Upside: +200.97%
Intellia Therapeutics
Nov 19, 2024
Maintains: Buy
Price Target: $90
Current: $13.12
Upside: +585.98%
Taysha Gene Therapies
Nov 15, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $2.01
Upside: +298.01%
Passage Bio
Nov 14, 2024
Maintains: Buy
Price Target: $13
Current: $0.51
Upside: +2,430.66%
Ultragenyx Pharmaceutical
Nov 12, 2024
Maintains: Buy
Price Target: $121
Current: $46.40
Upside: +160.78%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $109.40
Upside: +37.11%
Verve Therapeutics
Nov 6, 2024
Maintains: Buy
Price Target: $29 → $32
Current: $4.55
Upside: +603.30%
Vertex Pharmaceuticals
Nov 6, 2024
Maintains: Sell
Price Target: $361 → $408
Current: $447.41
Upside: -8.81%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Buy
Price Target: $366 → $384
Current: $248.79
Upside: +54.35%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $62.56
Upside: +34.27%
Oct 18, 2024
Maintains: Buy
Price Target: $16
Current: $2.22
Upside: +620.72%
Jun 25, 2024
Maintains: Buy
Price Target: $11 → $28
Current: $1.40
Upside: +1,900.00%
May 10, 2024
Maintains: Buy
Price Target: $87 → $86
Current: $16.17
Upside: +431.85%
Nov 8, 2022
Initiates: Buy
Price Target: $9
Current: $1.35
Upside: +566.67%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $88.63
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $8 → $16
Current: $0.78
Upside: +1,964.52%